TrialScientific reports2023

Phase II trial of delta-tocotrienol in neoadjuvant breast cancer with evaluation of treatment response using ctDNA.

Ina Mathilde Kjær et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.